1. Home
  2. APLM vs GLXG Comparison

APLM vs GLXG Comparison

Compare APLM & GLXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GLXG
  • Stock Information
  • Founded
  • APLM 2016
  • GLXG 2013
  • Country
  • APLM United States
  • GLXG Hong Kong
  • Employees
  • APLM N/A
  • GLXG N/A
  • Industry
  • APLM Blank Checks
  • GLXG
  • Sector
  • APLM Finance
  • GLXG
  • Exchange
  • APLM Nasdaq
  • GLXG NYSE
  • Market Cap
  • APLM 12.3M
  • GLXG 14.2M
  • IPO Year
  • APLM N/A
  • GLXG 2024
  • Fundamental
  • Price
  • APLM $7.02
  • GLXG $0.78
  • Analyst Decision
  • APLM Strong Buy
  • GLXG
  • Analyst Count
  • APLM 2
  • GLXG 0
  • Target Price
  • APLM $425.00
  • GLXG N/A
  • AVG Volume (30 Days)
  • APLM 7.4K
  • GLXG 113.9K
  • Earning Date
  • APLM 03-04-2025
  • GLXG 03-04-2025
  • Dividend Yield
  • APLM N/A
  • GLXG N/A
  • EPS Growth
  • APLM N/A
  • GLXG N/A
  • EPS
  • APLM N/A
  • GLXG 0.04
  • Revenue
  • APLM $2,101,000.00
  • GLXG $3,858,088.00
  • Revenue This Year
  • APLM N/A
  • GLXG N/A
  • Revenue Next Year
  • APLM N/A
  • GLXG N/A
  • P/E Ratio
  • APLM N/A
  • GLXG $17.68
  • Revenue Growth
  • APLM 70.54
  • GLXG N/A
  • 52 Week Low
  • APLM $6.38
  • GLXG $0.70
  • 52 Week High
  • APLM $80.50
  • GLXG $16.93
  • Technical
  • Relative Strength Index (RSI)
  • APLM 37.88
  • GLXG N/A
  • Support Level
  • APLM $6.70
  • GLXG N/A
  • Resistance Level
  • APLM $7.60
  • GLXG N/A
  • Average True Range (ATR)
  • APLM 0.70
  • GLXG 0.00
  • MACD
  • APLM -0.03
  • GLXG 0.00
  • Stochastic Oscillator
  • APLM 22.30
  • GLXG 0.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GLXG GALAXY PAYROLL GROUP LTD

Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.

Share on Social Networks: